ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2424

Peripheral Blood Mononuclear Cell Mitochondrial Bioenergetics Is Associated with Physical Performance in Patients with CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Ahmadi, Armin, University of California Davis, Davis, California, United States
  • Norman, Jennifer E., University of California Davis, Davis, California, United States
  • Begue, Gwenaelle, California State University Sacramento, Sacramento, California, United States
  • Vargas, Chenoa R., University of California Davis, Davis, California, United States
  • Rehman, Usman, University of California Davis, Davis, California, United States
  • Kim, Tae Youn, University of California Davis, Davis, California, United States
  • Langer, Henning, University of California Davis, Davis, California, United States
  • Jue, Thomas, University of California Davis, Davis, California, United States
  • Gamboa, Jorge, Vanderbilt University, Nashville, Tennessee, United States
  • Roshanravan, Baback, University of California Davis, Davis, California, United States
Background

Patients with CKD suffer from skeletal muscle dysfunction and impaired physical performance. Impaired muscle and systemic mitochondrial metabolism are central candidate mechanisms of skeletal muscle impairment in CKD. Live peripheral blood mononuclear cells (PBMC) mitochondrial bioenergetics may link altered metabolism in CKD with exercise intolerance. The association of PBMC bioenergetics with physical performance in CKD is unknown.

Methods

We recruited 13 participants with eGFR<60 ml/min/1.73m2. Cardiopulmonary fitness (absolute VO2 peak), total work performed, and work efficiency were measured using COSMED K5 wearable metabolic system during cycle ergometry testing. PBMC bioenergetics analysis were performed using the high resolution respirometry (Oroboros O2k). PBMC oxygen consumption rate was measured with sequential additions of pyruvate, oligomycin, FCCP, and antimycin A. We estimated basal, maximal uncoupled respiration (MUR) and spare respiratory capacity (SRC). SRC was defined as the difference between basal respiration and MUR. Pearson correlation coefficient was used to assess correlation of PBMC bioenergetics with muscle performance.

Results

The mean age of participants was 60.6 +/-9.5 years, eGFR was 35 +/-12.5 ml/min/1.73m2 and 53% were females. PBMC MUR correlated with total work (r= 0.57, P-value=0.041) and efficiency (absolute) (r=0.58, P-value=0.034). PBMC SRC correlated with total work (r=0.58, P-value=0.036) and efficiency (r=0.60, P-value=0.029). VO2 peak correlated with PBMC basal respiration (r=0.56, P-value=0.044), MUR (r=0.69, P-value=0.007), and SRC (r= 0.71, P-value=0.006).

Conclusion

These results suggest that PBMC respiration is strongly associated with exercise capacity and efficiency. Further studies are needed to investigate biologic determinants of PBMC bioenergetic health and its validity as a surrogate marker of skeletal muscle metabolic health in CKD.

Figure 1. Association of PBMC reserve capacity with A) total work efficiency and B) cardiorespiratory function (VO2 peak).

Funding

  • NIDDK Support –